文献速递淋巴瘤造血干细胞移植与细胞治疗

大B细胞淋巴瘤CD19 CAR-T治疗后晚期血细胞减少:细胞治疗联盟分析

Late cytopenia after CD19 chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a Cell Therapy Consortium analysis.
PubMed 文献 · Blood Adv · 2026-01-01

这项多中心回顾性研究纳入444例复发/难治大B细胞淋巴瘤患者,评估CD19 CAR-T后晚期血细胞减少的发生率、模式、危险因素及影响。输注后1、2、3、6、12个月可评估患者中3级及以上血细胞减少分别占47%、34%、19%、21%、11%。晚期血细胞减少与更高的1年非复发死亡率、更差的2年无进展生存和总生存相关。

要点

  • CD19 CAR-T后晚期血细胞减少常见,3个月时3级及以上者占19%。
  • 高危CAR-HEMATOTOX评分(≥2)可预测3个月时血细胞减少。
  • 晚期血细胞减少与1年非复发死亡率升高及2年生存变差相关。

核心结论

  • 晚期血细胞减少是CD19 CAR-T治疗后常见且具有临床意义的毒性。
  • 识别危险因素并持续监测对优化CAR-T后管理、降低治疗相关死亡至关重要。

研究设计与样本

  • 多中心回顾性研究,纳入2016年4月至2023年5月8个学术中心444例复发/难治大B细胞淋巴瘤患者。
  • 评估CD19 CAR-T后晚期血细胞减少的发生率、模式、危险因素及影响。

主要发现

  • 输注后1、2、3、6、12个月可评估患者中3级及以上血细胞减少分别占47%、34%、19%、21%、11%。
  • 307例血液学数据完整患者中,103例(33.6%)在30至100天之间出现符合晚期免疫效应细胞相关血液毒性的中性粒细胞减少。
  • 多变量分析显示高危CAR-HEMATOTOX评分(≥2)是3个月时血细胞减少的预测因素。
  • 桥接化疗和接受阿基仑赛与CAR-T后6个月时血细胞减少相关。
  • 晚期血细胞减少与更高的1年非复发死亡率(11% vs 4.4%;P = .038)、更差的2年无进展生存(38% vs 67%;P = .035)和更差的总生存(60% vs 76%;P = .016)相关。

临床怎么用

  • 对CD19 CAR-T治疗后患者应持续监测血细胞减少,尤其关注高危CAR-HEMATOTOX评分(≥2)者。
  • 识别桥接化疗和接受阿基仑赛等危险因素有助于优化CAR-T后管理。

局限性

  • 回顾性多中心研究,数据存在异质性,部分患者因复发、新治疗、死亡或失访被排除。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Late cytopenia (≥30 days after chimeric antigen receptor [CAR] T-cell therapy) is a significant complication after CD19-directed CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). However, available data remain limited and heterogeneous. In this retrospective multicenter study, we evaluated the incidence, patterns, risk factors, and impact of late cytopenia in patients treated with CD19 CAR T cells. A total of 444 patients with R/R LBCL treated at 8 academic centers within the Cell Therapy Consortium between April 2016 and May 2023 were included. After excluding patients with relapse, new treatment, death or lost to follow-up, grade ≥3 cytopenias were observed in 47%, 34%, 19%, 21%, and 11% of patients with available data at 1, 2, 3, 6, and 12 months after infusion. Among 307 patients with complete hematologic data, neutropenia consistent with late immune effector cell-associated hematotoxicity was identified in 103 patients (33.6%) between days 30 and 100. Multivariable analysis identified a high CAR-HEMATOTOX score (≥2) as a predictor of cytopenia at 3 months, whereas receipt of bridging chemotherapy and axicabtagene ciloleucel was associated with cytopenia at 6 months after CAR T-cell therapy. The presence of late cytopenia was associated with a higher 1-year nonrelapse mortality (11% vs 4.4%; P = .038), worse 2-year progression-free survival (38% vs 67%; P = .035), and worse 2-year overall survival (60% vs 76%; P = .016). In conclusion, late cytopenia is a common and clinically meaningful toxicity after CD19 CAR T-cell therapy. Recognition of risk factors and consistent monitoring are essential for optimizing post-CAR T-cell therapy care and reducing treatment-related mortality.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Wudhikarn K, Bromberg M, Brower J, et al. Late cytopenia after CD19 chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a Cell Therapy Consortium analysis. Blood Adv. 2026. PMID: 42341321. doi:10.1182/bloodadvances.2026019953

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。